RSC Publishing


Publishing

 

Cover image for Chemical Biology , click here for current issue

Chemical Biology

Chemical biology news and research from across RSC Publishing.



Bringing warhead efficiency to light


02 November 2007

US scientists can now compare molecular warheads that inactivate proteins.

"CALI can be used to knock-out the function of a protein"
Chromophore assisted light inactivation (CALI) of proteins involves generating highly reactive species (often singlet oxygen) from a chromophore (the warhead) using light. The reactive species damages the target protein, inactivating its biological function. Thomas Kodadek, a chemical biologist at University of Texas Southwestern Medical Centre, explained that CALI can be used to 'knock-out the function of a protein to validate pharmaceutical targets or alternatively provide temporal control of protein inactivation for mechanistic studies.'

CALI mechanism

In CALI, chromophores (red) produce reactive species to inactivate a target protein

Organic chromophores often react with the reactive species they produce, limiting their effectiveness as CALI warheads. In this new research, Kodadek and his co-workers have developed a system for comparing warhead effectiveness. The system allows different chromophores to be covalently attached to a standard target protein through a simple coupling mechanism. This allows the chromophore efficiencies to be compared by measuring the remaining activity of the target. 

Comparative experiments showed a ruthenium-based chromophore to be a more effective warhead than the commonly used organic dye fluorescein. The scientists demonstrated that the ruthenium chromophore can enter cells and inactivate a target, opening up the possibility of CALI experiments on living cells as well as cell extracts.

Russell Johnson

Link to journal article

A general system for evaluating the efficiency of chromophore-assisted light inactivation (CALI) of proteins reveals Ru(II) tris-bipyridyl as an unusually efficient warhead
Jiyong Lee, Peng Yu, Xiangshu Xiao and Thomas Kodadek, Mol. BioSyst., 2008, 4, 59
DOI: 10.1039/b712307h

Also of interest

A shining light in cancer research

A less invasive treatment for prostate cancer is a step closer thanks to preclinical studies by researchers in the US.